Blueprint Medicines Corporation
0HOJ.L
London Stock Exchange129.40
USD
+0.06
- -
Blueprint Medicines Corporation
0HOJ.L
(London Stock Exchange)
Recent
price
129.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Blueprint Medicines Corporation (Nasdaq: BPMC; LSE: 0HOJ) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes targeted therapies for genomically defined cancers and rare diseases. The company offers precision medicines including AYVAKIT (avapritinib) for systemic mastocytosis and gastrointestinal stromal tumors; AYVAKYT (avapritinib) in Europe for the same indications; GAVRETO (pralsetinib) for RET fusion-positive non-small cell lung cancer, thyroid cancer, and other solid tumors; and investigational therapies such as BLU-701, BLU-945, and BLU-451 targeting EGFR-driven lung cancers. Its pipeline also encompasses BLU-222 for oncology and BLU-782 for rare bone disorders, focusing on kinase inhibition and precision oncology across multiple modalities. Founded in 2011 and headquartered in Cambridge, Massachusetts, Blueprint Medicines operates primarily in the United States and Europe, targeting patients with rare genetic mutations through partnerships with global pharmaceutical firms. In recent developments, the company expanded its oncology portfolio with positive clinical data from the SYMPHONY trial for AYVAKIT in advanced systemic mastocytosis and advanced BLU-701 into Phase 1/2 trials for EGFR-mutated non-small cell lung cancer as of 2024; it also strengthened its strategic alliance with Roche for GAVRETO commercialization and reported successful funding from its at-the-market equity program to support pipeline advancement.